Sarepta (NASDAQ: SRPT) rumors are once again swirling, and shares are up 3% as a result. The company is often talked about as a possible candidate for a buyout because of its drug Eteplirsen, which has had incredible results treating Duchenne muscular dystrophy. The 3% jump today was due to a presentation by Vertex Pharmaceuticals (NASDAQ: VRTX) on its cystic fibrosis drug Kalydeco, which had several slides discussing Eteplirsen. Vertex has been mentioned in passing before as a possible interested party in Sarepta. Shares currently trade around $30 per share, but a recent upgrade from Piper Jaffray pegged the stock to go to anywhere between $60 and $80 in the short term, and possibly as high as $160.

David Williamson and The Motley Fool have no positions in the stocks mentioned above. Motley Fool newsletter services recommend Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.